199 related articles for article (PubMed ID: 30206771)
41. [Hypersexuality and other impulse control disorders in Parkinson's disease].
Nelis EA; Berendse HW; van den Heuvel OA
Ned Tijdschr Geneeskd; 2016; 160():A9359. PubMed ID: 26732226
[TBL] [Abstract][Full Text] [Related]
42. Minnesota Impulse Disorders Interview (MIDI): Validation of a structured diagnostic clinical interview for impulse control disorders in an enriched community sample.
Chamberlain SR; Grant JE
Psychiatry Res; 2018 Jul; 265():279-283. PubMed ID: 29772488
[TBL] [Abstract][Full Text] [Related]
43. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease.
Smith KM; Xie SX; Weintraub D
J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):864-70. PubMed ID: 26534930
[TBL] [Abstract][Full Text] [Related]
44. Psychopathology and comorbidity of psychiatric disorders in patients with kleptomania.
Baylé FJ; Caci H; Millet B; Richa S; Olié JP
Am J Psychiatry; 2003 Aug; 160(8):1509-13. PubMed ID: 12900315
[TBL] [Abstract][Full Text] [Related]
45. [Impulsive-compulsive syndrome in Parkinson's disease].
Nikitina AV; Fedorova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):32-8. PubMed ID: 23994929
[TBL] [Abstract][Full Text] [Related]
46. Depression as a Risk Factor for Impulse Control Disorders in Parkinson Disease.
Marín-Lahoz J; Sampedro F; Martinez-Horta S; Pagonabarraga J; Kulisevsky J
Ann Neurol; 2019 Nov; 86(5):762-769. PubMed ID: 31415102
[TBL] [Abstract][Full Text] [Related]
47. Prolactinoma-associated headache and dopamine agonist treatment.
Kallestrup MM; Kasch H; Østerby T; Nielsen E; Jensen TS; Jørgensen JO
Cephalalgia; 2014 Jun; 34(7):493-502. PubMed ID: 24351278
[TBL] [Abstract][Full Text] [Related]
48. [Clinical and psychopathological factors associated with impulse control disorders in Parkinson's disease].
Sáez-Francàs N; Martí Andrés G; Ramírez N; de Fàbregues O; Álvarez-Sabín J; Casas M; Hernández-Vara J
Neurologia; 2016 May; 31(4):231-8. PubMed ID: 26096669
[TBL] [Abstract][Full Text] [Related]
49. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
50. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Elenkova A; Shabani R; Kalinov K; Zacharieva S
Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
[TBL] [Abstract][Full Text] [Related]
51. Topiramate Overcoming Dopamine Agonist-Induced Migraine Exacerbation and Avoiding Transsphenoidal Surgery in a Young Boy With a Macroprolactinoma.
Faria AM; de F Presti P; Damiani D; Musolino NR; Neto MB
Headache; 2016 Oct; 56(9):1507-1511. PubMed ID: 27400437
[No Abstract] [Full Text] [Related]
52. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.
Barake M; Evins AE; Stoeckel L; Pachas GN; Nachtigall LB; Miller KK; Biller BM; Tritos NA; Klibanski A
Pituitary; 2014 Apr; 17(2):150-6. PubMed ID: 23504371
[TBL] [Abstract][Full Text] [Related]
53. Major depressive disorder induced by prolactinoma--a case report.
Liao WT; Bai YM
Gen Hosp Psychiatry; 2014; 36(1):125.e1-2. PubMed ID: 24182617
[TBL] [Abstract][Full Text] [Related]
54. MANAGEMENT OF ENDOCRINE DISEASE: Impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry?
Barake M; Klibanski A; Tritos NA
Eur J Endocrinol; 2018 Dec; 179(6):R287-R296. PubMed ID: 30324793
[TBL] [Abstract][Full Text] [Related]
55. Impulse control disorders and depression.
Lejoyeux M; Arbaretaz M; McLoughlin M; Adès J
J Nerv Ment Dis; 2002 May; 190(5):310-4. PubMed ID: 12011611
[TBL] [Abstract][Full Text] [Related]
56. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
Caputo C; Prior D; Inder WJ
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):906-13. PubMed ID: 25466526
[TBL] [Abstract][Full Text] [Related]
57. Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma.
Takeno A; Yamamoto M; Okazaki K; Yamaguchi T; Sugimoto T
Am J Case Rep; 2016 Mar; 17():160-4. PubMed ID: 26971354
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the utility of Liebowitz Social Anxiety Scale and Barratt Impulsiveness Scale in the diagnosis of social anxiety, impulsivity and depression.
Tyrała K; Seweryn M; Bonk M; Bulska W; Orszulak K; Bratek A; Krysta K
Psychiatr Danub; 2015 Sep; 27 Suppl 1():S223-6. PubMed ID: 26417767
[TBL] [Abstract][Full Text] [Related]
59. Impulse control disorder comorbidity among patients with bipolar I disorder.
Karakus G; Tamam L
Compr Psychiatry; 2011; 52(4):378-85. PubMed ID: 21683175
[TBL] [Abstract][Full Text] [Related]
60. Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis.
Antonini A; Chaudhuri KR; Boroojerdi B; Asgharnejad M; Bauer L; Grieger F; Weintraub D
Eur J Neurol; 2016 Oct; 23(10):1556-65. PubMed ID: 27425586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
